Roche says FDA grants priority review to hemophilia drug emicizumab

ZURICH (Reuters) - Swiss pharma group Roche said the U.S. Food and Drug Administration (FDA) granted priority review to its emicizumab for hemophilia A with inhibitors.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news